Receptor News and Research

RSS

A map of SARS-CoV-2 escape mutations enables the development of therapeutic antibody cocktails

A recent tour-de-force study by the US researchers describes a comprehensive approach to completely map mutations to the SARS-CoV-2 receptor-binding domain (RBD) that escape antibody binding – enabling, in turn, rational design of antibody therapeutics and appraisal of the antigenic consequences of viral evolution. The results are currently available in a bioRxiv preprint paper.

13 Sep 2020

Shedding light on altered blood cell traits involved in severe COVID-19

Researchers at the University of Georgia in the United States have shed light on the pathological mechanisms underlying the association between the genetic locus 3p21.31 and severe coronavirus disease 2019 (COVID-19).

13 Sep 2020

Researchers develop highly scalable, accurate antibody test for COVID-19

An antibody test for the virus that causes COVID-19, developed by researchers at The University of Texas at Austin in collaboration with Houston Methodist and other institutions, is more accurate and can handle a much larger number of donor samples at lower overall cost than standard antibody tests currently in use.

12 Sep 2020

Study sheds light on the disproportionate impact of COVID-19 on Blacks

In a study published in JAMA today, Mount Sinai researchers report findings that shed some light on the disproportionate impact of COVID-19 on Blacks, who have experienced rates of infection and death that are much greater, in some areas twice and three times more, than their proportion of the population.

11 Sep 2020

Simple blood tests can benefit women with breast cancer

A blood test that can identify a variety of mutations in advanced breast cancer can reliably match women to effective targeted treatments, early results of a major clinical trial reveal.

11 Sep 2020

Comprehensive analysis of antibody responses in COVID-19 patients can help develop effective vaccine

A comprehensive analysis of antibody responses in coronavirus disease 2019 (COVID-19) patients could inform the development of an effective vaccine, according to a study published September 10 in the open-access journal PLOS Pathogens by Chao Wu and Rui Huang of Nanjing University Medical School, and colleagues.

11 Sep 2020

New study brings researchers closer to a universal COVID-19 antibody test

A new study released by Houston Methodist takes researchers a significant step closer to developing a uniform, universal COVID-19 antibody test.

11 Sep 2020

Researchers explore IgA response to SARS-CoV-2

A new study published on the preprint server bioRxiv* and conducted by researchers from The Rockefeller University in New York examined the role of IgA antibodies in preventing SARS-CoV-2 infection. In this study, the team analyzed the IgA response to SARS-CoV-2 infection in 149 individuals.

10 Sep 2020

Researchers say Influenza may increase risk of COVID-19

A recent study by researchers suggests that the spread of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is influenced by influenza virus infection during the initial period of coronavirus disease 2019 (COVID-19) pandemic in Europe. The study is currently available on the medRxiv preprint server.

10 Sep 2020

Detecting SARS-CoV-2 in 30 seconds with cheap and sensitive nanotubes

In a fascinating new medRxiv preprint paper, researchers from the University of Nevada, Reno demonstrate the power of cobalt-functionalized titanium dioxide nanotubes by selectively detecting the spike glycoprotein of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in less than 30 seconds.

10 Sep 2020

Parkinson's disease drug may improve vision in patients with age-related macular degeneration

Investigators have determined that treating patients with an advanced form of age-related macular degeneration (AMD) with levodopa, a safe and readily available drug commonly used to treat Parkinson's disease, stabilized and improved their vision.

10 Sep 2020

Vapers, smokers, and non-smokers with chronic conditions have higher risks for COVID-19

What do vapers, smokers, and non-smokers with chronic conditions such as high blood pressure or diabetes have in common? They all are at higher risk for COVID-19.

10 Sep 2020

Computer-designed proteins can protect lab-grown human cells from SARS-CoV-2

Computer-designed small proteins have now been shown to protect lab-grown human cells from SARS-CoV-2, the coronavirus that causes COVID-19.

10 Sep 2020

Study: Small proteins block interaction between SARS-CoV-2 and human cell receptor

Using innovative computer-based approaches, researchers have developed protein inhibitors that block the interaction between the SARS-CoV-2 virus and human cell receptor ACE2.

10 Sep 2020

Sex-differential COVID-19 responses are mediated by kynurenic acid

Now, a new study by a research team from Yale University, USA, Edith Cowan University, Australia, and the University of Strathclyde, Scotland, and published on the preprint server medRxiv in September 2020 shows that kynurenic acid is the underlying factor which is responsible for these differences.

9 Sep 2020

Convalescent plasma fails to improve outcome of COVID-19 in India

A new study based in India and published on the medRxiv preprint server explores the role of convalescent plasma (CP) in the treatment of moderate COVID-19 within the limitations on resources faced in a developing country.

9 Sep 2020

Allergic immune response against bacteria is not pathological but protective

Allergy is one of the most common diseases in Europe, it is estimated that more than 150 million Europeans suffer from recurring allergies and by 2025 this could have increased to half of the entire European population.

9 Sep 2020

Susceptibility to SARS-CoV-2 infection varies across bat species

A recent study by researchers at Wuhan University, China, reveals that many bat species are not potential carriers of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) because of genetic mutations in angiotensin-converting enzyme 2 (ACE2) that prevent the entry of viruses inside bat cells. The study is currently available on the bioRxiv* preprint server.

9 Sep 2020

Study reveals how B cells react to SARS-CoV-2

In an exciting immunological medRxiv preprint paper, researchers from Germany and Russia analyzed adaptive immune response in severely affected patients with coronavirus disease (COVID-19). They demonstrated a protracted immune reaction characterized by egress of B lymphocytes into the blood.

9 Sep 2020

Pfizer, BioNTech COVID-19 vaccine candidate shows promise in preclinical study

Researchers in the United States and Germany have conducted a study demonstrating the preclinical efficacy of a new candidate vaccine against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the agent that causes coronavirus disease 2019 (COVID-19).

9 Sep 2020